Sionna Therapeutics says SION-719 Phase 2a trial misses sweat chloride endpoint in cystic fibrosis
Reuters2026/08/10 11:01- Sionna Therapeutics reported topline results from a Phase 2a cystic fibrosis trial of SION-719 added to Trikafta.
- The study failed to show the intended clinical activity, prompting the company to stop pursuing SION-719 as an add-on therapy.
- Management is reviewing trial confounders to guide next steps for its SION-451 dual-combination program.
- Separately, a Phase 1 healthy-volunteer study of SION-451 combinations met safety and drug-exposure objectives, with SION-451 plus SION-2222 selected as the preferred regimen.
- The company ended Q2 with about $268.3 million in cash, outlining plans to preserve capital while it reassesses development priorities.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
The 10-year U.S. Treasury yield climbs to 4.8%, erasing the dividend advantage of utility stocks; the sector’s rebound depends on interest rate stabilization rather than technical signals.
As U.S. Treasury yields continue to climb, the American utilities sector is experiencing a significant pullback—a rise in yields not only erodes the relative appeal of the sector’s dividends but also raises financing costs for the most capital-intensive industries within this market.
Euro holds gains above 1.1600 despite robust US jobs data, traders eye ECB rate decision
Port of Tauranga wins fast-track approval for Stella Passage development
Crypto prices
More
